Search results for: rituximab

FDA Issues Boxed Warning for Hydroxyurea & Neutropenia May Occur after Rituximab Treatments

Michele B. Kaufman, PharmD, BCGP | August 26, 2015

The FDA has issued a new boxed warning for Droxia (hydroxyurea). Also, according to a new study, RA patients receiving rituximab should be monitored for late-onset neutropenia…

Hepatitis Reaction with Rituximab Sparks Drug Safety Alert

M.J. Burton, MD, K.L. Winthrop, MD, MSPH, & J.W. Baddley, MD, MPH | January 1, 2015

The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation

ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

Mary Beth Nierengarten | February 1, 2013

Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists

Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders

From the College | May 16, 2025

This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.

Large International Study Says Flares Rare After COVID Vaccination

Catherine Kolonko | April 3, 2025

‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…

Flares Rare After COVID Vaccination

Catherine Kolonko | March 7, 2025

The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…

Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

Ruth Jessen Hickman, MD | March 6, 2025

Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…